A kidney cancer overview in plain terms
The experimental mRNA cancer vaccine, intismeran, has been tested in a phase 3 trial with 1,000+ melanoma patients. It is personalised to each patient by analysing tumors and targets neoantigens. When given with pembrolizumab, it aims to boost the immune response and extend cancer-free time. Results indicate reduced recurrence risk, but long-term survival remains to be seen. Trials also explore other cancers.
A new analysis shows a rise in cancers among people under 50 across England, the US and the Netherlands, driven by obesity, diet and lifestyle factors, with bowel, kidney and uterine cancers among the fastest-growing. Experts urge research and prevention as diagnosis at younger ages becomes more common.